Antiangiogenic Therapy in Gastroesophageal Cancer

Zhaohui Jin, Harry H. Yoon

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Antiangiogenesis therapy is one of only 2 biologically targeted approaches shown to improve overall survival over standard of care in advanced adenocarcinoma of the stomach or gastroesophageal junction (GEJ). Therapeutic targeting of vascular endothelial growth factor receptor 2 improves overall survival in patients with previously treated advanced gastric/GEJ adenocarcinoma. No antiangiogenesis therapy has demonstrated an overall survival benefit in patients with chemo-naïve or resectable esophagogastric cancer or in patients whose tumors arise from the esophagus. Promising ongoing clinical investigations include the combination of antiangiogenesis therapy with immune checkpoint inhibition and anti–human epidermal growth factor receptor 2 therapy.

Original languageEnglish (US)
Pages (from-to)499-510
Number of pages12
JournalHematology/Oncology Clinics of North America
Issue number3
StatePublished - Jun 2017


  • Angiogenesis
  • Checkpoint inhibitor
  • Esophageal cancer
  • Gastric cancer
  • Immunotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Antiangiogenic Therapy in Gastroesophageal Cancer'. Together they form a unique fingerprint.

Cite this